Mylan NV (MYL)

28.69
NASDAQ : Health Technology
Prev Close 29.25
Day Low/High 28.32 / 29.12
52 Wk Low/High 26.00 / 42.50
Avg Volume 5.50M
Exchange NASDAQ
Shares Outstanding 515.63M
Market Cap 15.08B
EPS 0.70
P/E Ratio 43.01
Div & Yield N.A. (N.A)

Latest News

Mylan To Present At Raymond James 40th Annual Institutional Investors Conference

Mylan To Present At Raymond James 40th Annual Institutional Investors Conference

HERTFORDSHIRE, England and PITTSBURGH, Feb. 28, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Falls on Fourth-Quarter Earnings and Guidance Miss

Mylan Falls on Fourth-Quarter Earnings and Guidance Miss

Shares of Mylan tumble after the generic drugmaker misses Wall Street's fourth-quarter earnings and 2019 forecast expectations.

Mylan Reports Fourth Quarter And Full Year 2018 Results And Provides 2019 Guidance

Mylan Reports Fourth Quarter And Full Year 2018 Results And Provides 2019 Guidance

HERTFORDSHIRE, England and PITTSBURGH, Feb. 26, 2019 /PRNewswire/ --  Mylan N.

Elon Musk, Jerome Powell, Home Depot, AT&T, Shake Shack - 5 Things You Must Know

Elon Musk, Jerome Powell, Home Depot, AT&T, Shake Shack - 5 Things You Must Know

U.S. stock futures decline amid a series of geopolitical risks that trimmed risked appetite; Federal Reserve Chairman Jerome Powell will testify before a Senate committee on Tuesday; the SEC asks a judge to hold Tesla's Elon Musk in contempt of court; Home Depot, Macy's and Palo Alto Networks report earnings.

Mylan Expected to Earn $1.35 a Share

Mylan Expected to Earn $1.35 a Share

Mylan revenue expected to fall 5.4% to $3.1 billion in latest quarter.

Mylan Launches Generic Suboxone® Sublingual Film To Treat Opioid Dependence

Mylan Launches Generic Suboxone® Sublingual Film To Treat Opioid Dependence

HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan To Release 2018 Fourth Quarter And Full Year Results And 2019 Guidance On Feb. 26, 2019

Mylan To Release 2018 Fourth Quarter And Full Year Results And 2019 Guidance On Feb. 26, 2019

HERTFORDSHIRE, England, and PITTSBURGH, Feb. 11, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Announces FDA Approval Of Wixela™ Inhub™ (fluticasone Propionate And Salmeterol Inhalation Powder, USP), First Generic Of ADVAIR DISKUS® (fluticasone Propionate And Salmeterol Inhalation Powder)

Mylan Announces FDA Approval Of Wixela™ Inhub™ (fluticasone Propionate And Salmeterol Inhalation Powder, USP), First Generic Of ADVAIR DISKUS® (fluticasone Propionate And Salmeterol Inhalation Powder)

Wixela™ Inhub™ is the first FDA-approved therapeutically equivalent generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or chronic obstructive pulmonary disease (COPD)

Mylan To Present At The 37th Annual J.P. Morgan Healthcare Conference

Mylan To Present At The 37th Annual J.P. Morgan Healthcare Conference

HERTFORDSHIRE, England and PITTSBURGH, Dec. 20, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Launch Of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering

Launch Of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering

Mesalamine Delayed-Release Tablets help individuals manage their ulcerative colitis.

Mylan Adds First Generic For Canasa® Rectal Suppository To Growing Gastroenterology Portfolio

Mylan Adds First Generic For Canasa® Rectal Suppository To Growing Gastroenterology Portfolio

Mylan's Mesalamine Rectal Suppository treats mildly to moderately active ulcerative proctitis

Sanofi's Formulation Patents On Multibillion-Dollar Lantus® Are Invalidated By U.S. Patent And Trademark Office Via IPR, Announces Mylan

Sanofi's Formulation Patents On Multibillion-Dollar Lantus® Are Invalidated By U.S. Patent And Trademark Office Via IPR, Announces Mylan

Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials

Mylan Expands Gastroenterology Portfolio With Launch Of Generic For Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets

Mylan Expands Gastroenterology Portfolio With Launch Of Generic For Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets

Mylan's Lansoprazole Delayed-Release Orally Disintegrating Tablets are approved to treat certain types of gastrointestinal ulcers

Mylan To Present At Nasdaq's 39th London Investor Conference

Mylan To Present At Nasdaq's 39th London Investor Conference

HERTFORDSHIRE, England and PITTSBURGH, Nov. 26, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Heat Biologics Inc. nosedived after the Durham, North Carolina-based biopharmaceutical company filed for a share offering pricing expected to hit $12 million.

Mylan Statement In Response To FDA Warning Letter Relating To Morgantown Plant

Mylan Statement In Response To FDA Warning Letter Relating To Morgantown Plant

HERTFORDSHIRE, England and PITTSBURGH, Nov. 20, 2018 /PRNewswire/ --  Mylan N.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.

Fab Five FAANG Stocks: Cramer's 'Mad Money' Recap (Tuesday 11/13/18)

Fab Five FAANG Stocks: Cramer's 'Mad Money' Recap (Tuesday 11/13/18)

Jim Cramer's got a different perspective on the recent performance of the companies we love to hate: Facebook, Amazon, Apple, Netflix, Google.

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Dropbox, Teva Pharmaceuticals, Salesforce, Linde, iQiyi and more.

Theravance Biopharma And Mylan Receive FDA Approval For YUPELRI™ (revefenacin) In Adults With Chronic Obstructive Pulmonary Disease

Theravance Biopharma And Mylan Receive FDA Approval For YUPELRI™ (revefenacin) In Adults With Chronic Obstructive Pulmonary Disease

YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US

Mylan Moves Up In Analyst Rankings, Passing TechnipFMC

Mylan Moves Up In Analyst Rankings, Passing TechnipFMC

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Mylan NV has taken over the #180 spot from TechnipFMC plc , according to ETF Channel. Below is a chart of Mylan NV versus TechnipFMC plc plotting their respective rank within the S&P 500 over time (MYL plotted in blue; FTI plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Mylan Shares Soar After Drugmaker's Earnings Top Forecasts

Mylan Shares Soar After Drugmaker's Earnings Top Forecasts

Shares of generic drugmaker Mylan soar after adjusted earnings top analysts' forecasts.

Mylan Reports Third Quarter 2018 Results And Reaffirms 2018 Guidance

Mylan Reports Third Quarter 2018 Results And Reaffirms 2018 Guidance

HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2018 /PRNewswire/ -- Mylan N.

Amazon, Warren Buffett and 'Bohemian Rhapsody' - 5 Things You Must Know

Amazon, Warren Buffett and 'Bohemian Rhapsody' - 5 Things You Must Know

U.S. stock futures are lower on Monday, as stronger-than-expected U.S. jobs data reignites bets on faster Federal Reserve rate hikes and as investors look ahead to the midterm elections on Tuesday; Amazon reportedly has held advanced talks about establishing its second headquarters in Crystal City, Virginia; 'Bohemian Rhapsody' makes $50 million in its opening weekend.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

TheStreet Quant Rating: C (Hold)